Fatty Acid Synthase Antibody

For Research Use Only. Not for Use in Diagnostic Procedures.

<table>
<thead>
<tr>
<th>Applications</th>
<th>Reactivity</th>
<th>Sensitivity</th>
<th>MW (kDa)</th>
<th>Source</th>
<th>UniProt ID</th>
<th>Entrez-Gene Id</th>
</tr>
</thead>
<tbody>
<tr>
<td>WB</td>
<td>H M</td>
<td>Endogenous</td>
<td>273</td>
<td>Rabbit</td>
<td>#P19096</td>
<td>14104</td>
</tr>
</tbody>
</table>

**Product Usage Information**

**Application**

Western Blotting

**Dilution**

1:1000

**Storage**

Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA and 50% glycerol. Store at –20°C. Do not aliquot the antibody.

**Specificity / Sensitivity**

Fatty Acid Synthase Antibody detects endogenous levels of total fatty acid synthase protein.

**Source / Purification**

Polyclonal antibodies are produced by immunizing animals with a synthetic peptide around Ala1160 corresponding to a sequence of mouse fatty acid synthase. Antibodies are purified by protein A and peptide affinity chromatography.

**Background**

Fatty acid synthase (FASN) catalyzes the synthesis of long-chain fatty acids from acetyl-CoA and malonyl-CoA. FASN is active as a homodimer with seven different catalytic activities and produces lipids in the liver for export to metabolically active tissues or storage in adipose tissue. In most other human tissues, FASN is minimally expressed since they rely on circulating fatty acids for new structural lipid synthesis (1). According to the research literature, increased expression of FASN has emerged as a phenotype common to most human carcinomas. For example in breast cancer, immunohistochemical staining showed that the levels of FASN are directly related to the size of breast tumors (2). Research studies also showed that FASN is highly expressed in lung and prostate cancers and that FASN expression is an indicator of poor prognosis in breast and prostate cancer (3-5). Furthermore, inhibition of FASN is selectively cytotoxic to human cancer cells (5). Thus, increased interest has focused on FASN as a potential target for the diagnosis and treatment of cancer as well as metabolic syndrome (6,7).

**Background References**


**Species Reactivity**

Species reactivity is determined by testing in at least one approved application (e.g., western blot).

**Western Blot Buffer**

IMPORTANT: For western blots, incubate membrane with diluted primary antibody in 5% w/v BSA, 1X TBS, 0.1% Tween® 20 at 4°C with gentle shaking, overnight.

**Applications Key**

**Cross-Reactivity Key**


**Trademarks and Patents**

Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc. All other trademarks are the property of their respective owners. Visit cellsignal.com/trademarks for more information.

**Limited Uses**

Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer’s terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.